← Eichor
Study identifier: NCT07432360 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Detecting Clinically Significant Prostate Cancer With Advanced MRI Protocols and Extensive Histopathology

Condition: Prostate Cancer  ·  Sponsor: Virdx, Inc.

PhaseN/A
Planned participants300
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

In recent years, new and promising approaches have emerged in the field of MRI imaging of the prostate. These approaches usually aim to visualise the so-called "microstructures" of the tissue and are intended to offer greater accuracy in the diagnosis of prostate cancer than the current mpMRI examination. To this end, mathematical microstructure models are calculated that determine the proportional presence of histological substructures in specific MRI volumes. Additional new MRI sequences that are not routinely recorded are required to calculate the microstructure models. In order to further investigate the possibilities of these new MRI sequences, this study will compare different mathematical models. In addition, a histopathological examination of the tissue will be performed.

This description comes directly from the study's public registry record.

Talk to the study team

Sina Knapp, PhD  ·  +4917680891277  ·  sina.knapp@virdx.com

Always discuss trial participation with your own doctor first.

Locations (1)

Instituto do Câncer do Estado de São PauloSão Paulo, BrazilRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07432360